文献速递新发突发、热带与寄生虫病

伯氨喹预防尼泊尔间日疟短期和长期复发的疗效

Efficacy of Primaquine in Preventing Short- and Long-Latency Plasmodium vivax Relapses in Nepal.
PubMed 文献 · J Infect Dis · 2019-01-01

在尼泊尔开展随机试验,间日疟患者分别接受氯喹单药或氯喹联合伯氨喹(0.25 mg base/kg/天×14天)治疗并随访1年。基因分型显示部分复发为长潜伏期,联合方案可提供根治。

要点

  • 氯喹联合标准剂量14天伯氨喹可显著降低间日疟复发。
  • 完成1年随访者中联合组复发4.1%,单药组28.2%。
  • 基因分型发现部分同源复发在9个月后聚集,提示长潜伏期。

核心结论

  • 氯喹联合标准剂量14天伯氨喹方案在尼泊尔对短期和长期潜伏的间日疟提供高效根治。

研究设计与样本

  • 随机对照试验,间日疟患者随机接受氯喹单药(25 mg base/kg分3天)或联合伯氨喹(0.25 mg base/kg/天×14天)。
  • 对寄生虫分离株进行基因分型。

主要发现

  • 联合组完成1年随访的73例中复发3例(4.1%),氯喹单药组78例中复发22例(28.2%)。
  • 微卫星基因分型显示间日疟原虫遗传多样性较高(平均杂合度0.843,范围0.570-0.989),感染多重度低(平均1.05)。
  • 12例基因同源复发中5例(42%)在9个月后聚集出现,提示长潜伏期。

关键数值与推荐

  • 伯氨喹剂量为0.25 mg base/kg/天,疗程14天。
  • 氯喹剂量为25 mg base/kg,分3天给予。

临床怎么用

  • 在尼泊尔等间日疟流行区,对间日疟患者可采用氯喹联合标准剂量14天伯氨喹以实现根治。
  • 需关注氯喹耐药可能,但联合方案仍显示高效。

局限性

  • 原文未明确报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Plasmodium vivax is the main cause of malaria in Nepal. Relapse patterns have not been characterized previously. METHODS: Patients with P. vivax malaria were randomized to receive chloroquine (CQ; 25 mg base/kg given over 3 days) alone or together with primaquine (PQ; 0.25 mg base/kg/day for 14 days) and followed intensively for 1 month, then at 1- to 2-month intervals for 1 year. Parasite isolates were genotyped. RESULTS: One hundred and one (49%) patients received CQ and 105 (51%) received CQ + PQ. In the CQ + PQ arm, there were 3 (4.1%) recurrences in the 73 patients who completed 1 year of follow-up compared with 22 of 78 (28.2%) in the CQ-only arm (risk ratio, 0.146 [95% confidence interval, .046-.467]; P < .0001). Microsatellite genotyping showed relatively high P. vivax genetic diversity (mean heterozygosity, 0.843 [range 0.570-0.989] with low multiplicity of infection (mean, 1.05) reflecting a low transmission preelimination setting. Of the 12 genetically homologous relapses, 5 (42%) occurred in a cluster after 9 months, indicating long latency. CONCLUSIONS: Although there may be emerging CQ resistance, the combination of CQ and the standard-dose 14-day PQ regimen is highly efficacious in providing radical cure of short- and long-latency P. vivax malaria in Nepal.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Rijal KR, Adhikari B, Ghimire P, et al. Efficacy of Primaquine in Preventing Short- and Long-Latency Plasmodium vivax Relapses in Nepal. J Infect Dis. 2019. PMID: 30882150. doi:10.1093/infdis/jiz126

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。